close

News

LATEST POSTS from News

Endeavor BioMedicines gains rights to lead ULK1/2 inhibitor molecule

Endeavor BioMedicines gains rights to lead ULK1/2 inhibitor molecule Endeavor BioMedicines, a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis, has concluded an exclusive licensing agreement with the Salk Institute, along with Sanford Burnham Prebys. Under the license agreement, the California-based company…..

TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies

TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series…..

Clean Biologics is acquiring Biodextris

Clean Biologics is acquiring Biodextris  Clean Biologics, a French group providing services to the biopharmaceutical industry,  is acquiring Biodextris, a Contract Development and Manufacturing Organization (CDMO) based in Laval (Montreal), Canada. Biodextris provides analytical and process development, early-phase clinical manufacturing and quality control testing services for clients in the vaccine…..

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases  ConserV Bioscience, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA, a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its TriMix technology,…..